Groupama Asset Managment Sells 749,075 Shares of Axon Enterprise, Inc $AXON

Groupama Asset Managment decreased its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 99.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,759 shares of the biotechnology company’s stock after selling 749,075 shares during the period. Groupama Asset Managment’s holdings in Axon Enterprise were worth $747,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in AXON. Evergreen Capital Management LLC increased its position in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares during the period. Synergy Financial Group LTD boosted its position in shares of Axon Enterprise by 1.4% in the third quarter. Synergy Financial Group LTD now owns 1,388 shares of the biotechnology company’s stock valued at $996,000 after acquiring an additional 19 shares during the period. Tower Research Capital LLC TRC grew its stake in Axon Enterprise by 1.2% during the second quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock valued at $1,350,000 after acquiring an additional 19 shares in the last quarter. Certuity LLC increased its holdings in Axon Enterprise by 5.1% during the 4th quarter. Certuity LLC now owns 474 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 23 shares during the period. Finally, Pure Financial Advisors LLC increased its holdings in Axon Enterprise by 6.7% during the 4th quarter. Pure Financial Advisors LLC now owns 364 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 23 shares during the period. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $527.76 on Monday. Axon Enterprise, Inc has a 52-week low of $339.01 and a 52-week high of $885.91. The company has a fifty day moving average of $497.09 and a 200-day moving average of $475.52. The company has a market capitalization of $42.54 billion, a P/E ratio of 211.95, a P/E/G ratio of 10.77 and a beta of 1.39. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.93 and a current ratio of 2.27.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.90 million. During the same quarter last year, the business posted $1.47 earnings per share. The company’s revenue for the quarter was up 33.7% on a year-over-year basis. As a group, equities research analysts predict that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on AXON shares. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Friday, July 10th. Piper Sandler increased their price objective on Axon Enterprise from $674.00 to $724.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. UBS Group dropped their price objective on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating for the company in a research note on Thursday, May 7th. Weiss Ratings upgraded Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Finally, The Goldman Sachs Group set a $535.00 price target on Axon Enterprise in a report on Thursday, May 7th. Fifteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $725.25.

Insider Activity at Axon Enterprise

In related news, insider Elizabeth Reid Coughlin sold 1,554 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $485.00, for a total value of $753,690.00. Following the completion of the sale, the insider owned 34,024 shares in the company, valued at $16,501,640. The trade was a 4.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, President Joshua Isner sold 13,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $488.45, for a total value of $6,349,850.00. Following the completion of the sale, the president directly owned 169,125 shares of the company’s stock, valued at approximately $82,609,106.25. This represents a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 58,989 shares of company stock worth $30,527,983 in the last quarter. 4.20% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.